Cross-Border M&A Accelerates in Q2 2026: Five Deals Redefining Biopharma, Industrials, and Infrastructure
Five M&A transactions announced in a single week — led by UCB’s acquisition of Neurona Therapeutics and Badger Meter’s $100M UK deal — reveal accelerating cross-border consolidation across biopharma, industrials, and health tech in Q2 2026. Decision-makers must navigate expanding regulatory obligations and due diligence complexity to protect deal value.